Drug Trial Radar · NCT06052748
A Study to Evaluate the Efficacy and Safety of AD-223
Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
502
Actual
Start
Feb 15, 2024
Primary completion
Mar 27, 2025
Study completion Apr 2, 2025
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of AD-223
Conditions
- Hypertension,Essential
Interventions
AD-223ADrug
PO, Once daily(QD), 8weeks
AD-223BDrug
PO, Once daily(QD), 8weeks
AD-223CDrug
PO, Once daily(QD), 8weeks
AD-223A PlaceboDrug
PO, Once daily(QD), 8weeks
AD-223B PlaceboDrug
PO, Once daily(QD), 8weeks
AD-223C PlaceboDrug
PO, Once daily(QD), 8weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change rate of MSSBPTime frame: Baseline, Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanyang University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.